TiGenix files for $43M IPO to fund stem cell therapy ph3 – FierceBiotech
FierceBiotech |
TiGenix files for $43M IPO to fund stem cell therapy ph3
FierceBiotech TiGenix has taken another step toward its delayed Nasdaq IPO. The stem cell therapy specialist is aiming to net $42.9 million (€39.8 million) through the listing, approximately half of which will go toward a U.S. late-phase trial of Crohn's disease … |
